PCM
VERV

Pentwater Capital Management’s Verve Therapeutics VERV Stock Holding History

Pentwater Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,720,000
Closed -$75.5M – 141
2025
Q2 		$75.5M Buy
+6,720,000
New +$38.3M 0.49% 40

Other funds holding VERV

GCM
Greenland Capital Management New York $812M AUM 45.54% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Pentwater Capital Management's VERV Position: Q3 2025 in Review

Pentwater Capital Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 6,720,000 shares — an estimated $75.5M sold.

Pentwater Capital Management first reported a position in VERV in Q2 2025 and held it in 1 quarter. The position peaked at $75.5M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Pentwater Capital Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Pentwater Capital Management sold 6,720,000 Verve Therapeutics shares in Q3 2025, an estimated $75.5M.
  • Pentwater Capital Management first reported a position in Verve Therapeutics in Q2 2025 and held it in 1 quarter.
  • Pentwater Capital Management's Verve Therapeutics position peaked at $75.5M in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Pentwater Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.